Did You Know? |
- Some medications have earned legendary status for their life-saving power and global reach. Penicillin, discovered in 1928, launched the antibiotic era and has saved over 200 million lives. Insulin, introduced
in 1922, turned diabetes from a death sentence into a manageable condition. Aspirin, one of the most widely used drugs worldwide, eases pain, curbs inflammation, and even helps prevent heart attacks. Morphine
remains a cornerstone of serious pain management, while vaccines for smallpox and polio—though not technically medications—have eradicated or nearly eliminated once-devastating diseases.
- In the U.S., hydrocodone leads the prescription race with 131.2 million annual scripts for pain relief, followed by simvastatin (94.1 million) for high cholesterol and
lisinopril (87.4 million) for blood pressure and heart failure. Levothyroxine supports 70.5 million Americans with thyroid issues, amlodipine (57.2 million) tackles hypertension and angina, and
omeprazole (53.4 million) soothes digestive woes. Amoxicillin remains a go-to antibiotic with 52.3 million prescriptions, and metformin helps manage type 2 diabetes for 48.3 million patients annually.
From ancient remedies to modern marvels, these drugs have reshaped healthcare and touched billions of lives.
- From the first jab to the latest genetic leap, the history of medicine is a thrilling timeline of breakthroughs that reshaped humanity. It all began in 1796 when Edward Jenner’s smallpox vaccine sparked
the age of immunization, followed by the 1846 discovery of anesthesia, which turned surgery from a brutal ordeal into a bearable procedure. In 1921, insulin gave diabetics a lifeline, and just seven years later,
Alexander Fleming’s accidental encounter with penicillin revolutionized infection control. The 1950s brought the polio vaccine and the first organ transplant, while the 1960s introduced the oral contraceptive pill,
empowering reproductive choice. Fast forward to 2003, the Human Genome Project cracked the code of life, paving the way for personalized medicine. And in 2020, the lightning-fast development of COVID-19 vaccines
showcased the power of mRNA technology and global collaboration. Each milestone didn’t just save lives—it redefined what medicine could do, turning science fiction into everyday reality.
- Timeline of major medication breakthroughs - These milestones didn’t just save lives—they reshaped how we think about disease, prevention, and treatment.
- 1796 – Smallpox Vaccine: Edward Jenner’s cowpox-based inoculation laid the foundation for modern immunology.
- 1846 – Anesthesia: William Morton’s public demonstration of ether revolutionized surgery by making it pain-free.
- 1921 – Insulin: Frederick Banting and Charles Best discovered insulin, turning diabetes from a fatal disease into a manageable condition.
- 1928 – Penicillin: Alexander Fleming’s accidental discovery of penicillin ushered in the antibiotic era, saving millions from bacterial infections.
- 1955/1961 – Polio Vaccines: Jonas Salk and Albert Sabin developed injectable and oral vaccines that nearly eradicated polio worldwide.
- 1960 – Oral Contraceptive Pill: Approved in the U.S., it gave women unprecedented control over reproductive health.
- 1980s – Hepatitis B Vaccine: A major step in preventing liver disease and cancer.
- 1990s – Antiretroviral Therapy (ART): Transformed HIV/AIDS from a deadly diagnosis to a manageable chronic condition.
- 2003 – Human Genome Project Completion: Enabled personalized medicine and targeted therapies.
- 2020 – COVID-19 Vaccines: Developed and distributed globally within a year, showcasing the power of mRNA technology and global collaboration.
- Over-the-counter (OTC) medications are the unsung heroes of home healthcare—ready to tackle everything from sniffles to stomachaches without a prescription, some of the most commonly used ones:
- Pain & Fever Relief
- Acetaminophen (Tylenol): For pain and fever
- Ibuprofen (Advil, Motrin): A nonsteroidal anti-inflammatory drug (NSAID)
- Naproxen (Aleve): Longer-lasting NSAID
- Aspirin: Also used for heart health in low doses
- Allergy Relief
- Loratadine (Claritin), Cetirizine (Zyrtec), Fexofenadine (Allegra): Non-drowsy antihistamines
- Diphenhydramine (Benadryl): Older antihistamine, more sedating
- Fluticasone (Flonase), Triamcinolone (Nasacort): Nasal corticosteroids
- Cold & Cough Remedies
- Dextromethorphan: Cough suppressant
- Guaifenesin: Expectorant to loosen mucus
- Pseudoephedrine (Sudafed), Phenylephrine: Decongestants
- Digestive Aids
- Loperamide (Imodium): Anti-diarrheal
- Bismuth subsalicylate (Pepto-Bismol): Upset stomach and diarrhea
- Calcium carbonate (Tums), Famotidine (Pepcid), Omeprazole (Prilosec): For heartburn and acid reflux
- Sleep Aids
- Diphenhydramine and Doxylamine: Found in many nighttime formulas
- Topical Treatments
- Hydrocortisone cream: For itching and inflammation
- Bacitracin or Neosporin: Antibiotic ointments
- Antifungals like clotrimazole or miconazole: For athlete’s foot or yeast infections
- The generic name for Tylenol is acetaminophen, which is one of the most widely used pain relievers out there—often the first line of defense for everything from headaches to fevers. It's also known as paracetamol in
many countries outside the U.S.
- Benlysta is the only treatment on the market specifically for
Lupus, a disease in which the body's immune system attacks healthy issue, including skin, joints, kidneys or the brain.
This prescription medicine is expensive; the patient needs to have at least 2 doses a month, each costs $3,330 per dose.
- The generic high blood pressure (hypertension) drug
Lisinopril was prescribed and refilled around 37 million times by more than 7 million American Medicare patients at a cost of $307
million in 2013. Total U.S. prescriptions for Lisinopril reached nearly 98 million or 2.94 billion pills by 2020 at the cost of up to $600 million, and that number has likely continued to grow given the
aging population and rising rates of hypertension.
- Certain antidepressants—especially SSRIs (selective serotonin reuptake inhibitors)—have been
linked to an increased risk of bleeding, including rare cases of intracranial hemorrhage,
the absolute risk remains very low for most people. The risk increases significantly when SSRIs are combined with NSAIDs, antiplatelet drugs, or anticoagulants.
- An incredibly rare isotope called Actinium-225 could revolutionize the way we treat cancer. Preliminary trials have obliterated cancer in patients given only weeks to live.
There's only one problem is that it's almost impossible to obtain. Actinium-225 (Ac-225) is a radioactive isotope being studied for its potential in targeted alpha therapy (TAT),
a form of radiotherapy that delivers powerful, localized radiation directly to cancer cells while sparing healthy tissue. Early trials, especially in prostate cancer and leukemia,
have shown remarkable results, including cases where tumors shrank dramatically in patients with very limited options2. Ac-225 is extremely scarce. It’s produced in only a few
facilities worldwide, and the process is complex and expensive. Until recently, most of the supply came from decaying thorium stockpiles or small-scale reactors.
- As of 2025, Keytruda has topped the list of best selling drugs in the world; a cancer immunotherapy developed by Merck, Keytrudas is used to treat a wide range of cancers,
including melanoma, non-small cell lung cancer, and head and neck cancers. Keytruda works by helping the immune system recognize and attack cancer cells, and its success
has been driven by its expanding list of approved uses—over 40 indications globally. Its projected global revenue for 2025 is a staggering $31 billion, making it
the leader in pharmaceutical sales.
- Xanax (alprazolam) is primarily prescribed to treat anxiety disorders, including generalized anxiety disorder (GAD) and panic disorder, and manage anxiety associated with depression.
Xanax belongs to a class of medications called benzodiazepines, which work by enhancing the effects of a calming neurotransmitter in the brain called GABA. This helps reduce feelings
of nervousness, tension, and panic. Xanax is also used to treat panic disorders with or without a fear of places and situations that might cause panic, helplessness, or
embarrassment.
- While the most expensive medications often have no direct substitutes, there are ways to reduce costs and find more affordable alternatives.
- Generic Medications – Many brand-name drugs have generic versions that are significantly cheaper while maintaining the same effectiveness.
- Patient Assistance Programs – Some pharmaceutical companies offer financial aid or free medications to eligible patients.
- Pharmacy Coupons & Discount Cards – Services like GoodRx and NeedyMeds provide discounts on prescription drugs.
- Insurance Formulary Options – Checking your insurance plan’s drug formulary can help identify lower-cost alternatives.
- Prescription Pricing Tools – Some healthcare providers use tools like SwiftRx Direct to find cost-effective medications.
- The Most-Favored-Nation (MFN) pricing policy aims to lower drug costs in the U.S. by ensuring that Americans pay no more than patients in other developed countries.
This could have a significant impact on insulin prices, which have been notoriously high in the U.S. Insulin is a hormone produced by the pancreas that plays
a crucial role in regulating blood sugar levels. It acts like a key, allowing glucose to enter cells for energy, and it also helps the body store excess glucose for later use.
In diabetes, the body either doesn't produce enough insulin or can't effectively use the insulin it does produce, leading to high blood sugar levels. While this policy
could lead to major price cuts, some experts warn that implementation challenges and legal battles could delay its effects. Under the policy some key aspects include:
- Direct-to-Consumer Purchasing – The government is pushing for manufacturers to sell insulin at the lowest international price.
- Price Matching – If insulin is sold for less in another country, manufacturers may be required to offer the same price in the U.S.
- Government Enforcement – If companies fail to comply, the administration has pledged to take aggressive action to ensure price reductions.
- Recent policies in the U.S. are aiming to lower drug prices, particularly through the Most-Favored-Nation (MFN) pricing model introduced by Trump's administration.
This policy seeks to align U.S. drug prices with the lowest prices paid by economically comparable countries. The administration argues that Americans have been
overpaying for medications while other nations benefit from lower costs. While the policy aims to reduce costs, experts warn that implementation challenges and
legal battles could delay its effects. Some pharmaceutical companies and trade groups have opposed the measure, arguing it could disrupt innovation and access
to new treatments. Some key aspects of the policy include:
- Price Matching – Drug manufacturers must offer U.S. consumers the lowest price available in other developed countries.
- Government Action – If companies fail to comply, the administration has pledged to take aggressive measures to enforce price reductions.
- Impact on Biosimilars – The policy may encourage competition from biosimilars, which are lower-cost alternatives to brand-name biologic drugs.
- Medicines in the U.S. are often more expensive than in other countries due to several key factors.
- No Single-Payer Negotiation – Unlike many countries where the government negotiates drug prices, the U.S. relies on private insurers, which weakens bargaining power.
- Lack of Government Price Regulation – Many nations have price caps on medications, but in the U.S., pharmaceutical companies set their own prices.
- Patent System & Limited Competition – Drug makers use patents to prevent generic alternatives from entering the market, keeping prices high.
- Complex Reimbursement System – The U.S. healthcare system is fragmented, with multiple insurers and intermediaries, making pricing less transparent.
- High Research & Development Costs – Pharmaceutical companies argue that high prices help fund innovation and new drug development.
- Cancer treatments are often expensive due to research, development, and the complexity of personalized therapies. Some of the most expensive cancer medications in the U.S. include:
- Kimmtrak – A treatment for uveal melanoma, one of the most expensive cancer drugs.
- Danyelza – Used for neuroblastoma, costing around $1.2 million annually.
- CAR-T Cell Therapies – Treatments like Yescarta and Kymriah for blood cancers can cost hundreds of thousands per dose.
- Immunotherapies – Drugs like Keytruda and Opdivo, which are widely used for various cancers, can cost tens of thousands per month.
- The most expensive medicines in the US include Lenmeldy, Hemgenix, Elevidys, Zolgensma and Zokinvy, with Lenmeldy being the most expensive drug in America, costing an average one-time cost of $4.25 million.
Hemgenix, another high-cost drug, has a wholesale acquisition cost of $3.5 million. These drugs are often used for rare and complex conditions and require special handling and close oversight from specialists.
The high prices are attributed to the curative potential, advanced technologies, and relatively small target populations.
- Lenmeldy – $4.25 million per treatment, used for metachromatic leukodystrophy (MLD).
- Hemgenix – $3.5 million per dose, a gene therapy for hemophilia B.
- Elevidys – $3.2 million per treatment, used for Duchenne muscular dystrophy (DMD).
- Zolgensma – $2.1 million for a one-time dose, treats spinal muscular atrophy.
- Zokinvy – Over $1 million per year, used for a rare genetic disorder.
- Zolgensma, Zolgensma, Lenmeldy, Hemgenix, Zokinvy, Myalept, and Mavencladare some of the most expensive prescription medicines in the U.S. These prescriptions are
incredibly expensive, often due to their specialized nature and the costs associated with their development and production.
- Zolgensma: This gene therapy costs around $2.1 million for a one-time treatment; it's used to treat spinal muscular atrophy, a rare childhood disorder.
- Lenmeldy: Priced at $4.25 million per treatment, Lenmeldy is used for metachromatic leukodystrophy, a rare genetic disease.
- Hemgenix: This drug costs $3.5 million for a one-time dose and is used to treat hemophilia B, a lifelong bleeding disorder.
- Zokinvy: An orphan drug for treating a rare genetic condition, Zokinvy costs around $1,073,760 per year.
- Myalept: Used for treating leptin deficiency, Myalept costs over $60,000 per month.
- Mavenclad: This medication for multiple sclerosis also costs over $60,000 per month.
- Penicillin was among the first medications to be effective against many bacterial infections caused by staphylococci and streptococci.
It has been widely used for various bacterial infections.
- Discovery: Penicillin was discovered by Scottish bacteriologist Alexander Fleming in 1928. While working at St. Mary's Hospital in London, Fleming noticed that a mold called Penicillium notatum had contaminated
one of his Petri dishes and killed the surrounding bacteria.
- Development: Fleming's initial discovery was groundbreaking, but it took several years for penicillin to be developed into a usable drug. In the late 1930s, a team at the Sir William Dunn School of Pathology at Oxford University,
led by Howard Florey and Ernst Chain, successfully isolated and purified penicillin.
- Mass Production: During World War II, the need for effective antibiotics became urgent. The United States and other Allied countries ramped up production of penicillin, which played a crucial role in treating infections in
wounded soldiers.
- Nobel Prize: In 1945, Fleming, Florey, and Chain were awarded the Nobel Prize in Physiology or Medicine for their work on penicillin.
- Post-War Era: After the war, penicillin became widely available and revolutionized the treatment of bacterial infections. Researchers continued to develop new types of penicillin, including semisynthetic variants
that are more effective against a broader range of bacteria.
- Modern Use: Penicillin remains one of the most widely used antibiotics today, although the rise of antibiotic resistance has become a significant challenge.
- When it comes to treating severe asthma, there are several medications and treatment options available:
- Quick-Relief Medications (Rescue Medications) - Taken as needed for rapid relief during an asthma attack.
- Short-Acting Beta Agonists: Examples include Albuterol and Levalbuterol.
- Ipratropium (Atrovent HFA): Helps open airways.
- Oral Corticosteroids: Used for severe asthma attacks.
- Medications for Allergy-Induced Asthma - Taken regularly or as needed to reduce sensitivity to specific allergens.
- Allergy Shots (Immunotherapy): Gradually desensitize the immune system to allergens.
- Under-the-Tongue Immunotherapy Tablets: An alternative to shots.
- Allergy Medications: Antihistamines, Decongestants, etc.
- Biologics - Used alongside control medications to target specific biological responses causing lung inflammation.
- Examples include Benralizumab, Dupilumab, Mepolizumab, Omalizumab, Reslizumab, and Tezepelumab-ekko
- Long-Term Control Medications - These are taken regularly to manage chronic symptoms and prevent asthma attacks. They are crucial for most people with asthma.
- Inhaled Corticosteroids: These anti-inflammatory drugs are highly effective and commonly used. They reduce airway swelling and tightening. Examples include Fluticasone, Budesonide, Mometasone, Beclomethasone, and Ciclesonide.
- Leukotriene Modifiers: These help control inflammation and include medications like montelukast and zafirlukast.
- Long-Acting Beta Agonists (LABAs): These help dilate airways and are often combined with inhaled corticosteroids.
- Long-Acting Muscarinic Antagonists (LAMAs): These also help relax airway muscles and improve airflow.
- Combination Inhalers: These contain both corticosteroids and LABAs.
- Decongestant found in cold, allergy medicines doesn’t actually work; many popular over-the-counter drugs that use
phenylephrine to treat cough, sinus and flu symptoms, will be removed from U.S. store shelves.
- A study has found that Tylenol or generic acetaminophen, when taken at high doses or for extended periods by pregnant women, can put their child at a
higher risk of developing attention deficit hyperactivity disorder or
autism spectrum disorder. Children whose cord blood samples contained the highest levels of acetaminophen were roughly three times more likely to be diagnosed with
autism later in childhood.
- Antibiotics don't work for viruses like colds and the
flu.
- The most common cholesterol lowering drugs are called statins, which help to lower cholesterol
and maintain the integrity of arteries.
- Some drugs work together, complementing or backing up each other. Others compete or get in each other's way. Aspirin and Plavix (generic name:
clopidogrel) make a good tag team, combining to prevent heart attacks and strokes. Stomach pain is not a common side effect of
Plavix or aspirin, which are used to prevent heart attacks and strokes in persons with heart disease (recent heart attack), recent stroke, or blood
circulation disease (peripheral vascular disease). However, stomach pain with bleeding are a possible side effect of
Plavix and/or aspirin. Patients who have stomach pain or cramping while taking these drugs, there's a small chance they could have bleeding in your stomach. The H-2 Blocker family, which include Johnson & Johnson's
Mylanta and Boehringer Ingelheim's Zantac
can reduce acid while taking Plavix and/or aspirin.
- Taking aspirin or anti-clotting medicines like Plavix
won't boost the risk of another stroke
if you have already survived a bleeding stroke, and they might even help guard against a second brain bleed.
Aspirin therapy reduces the clumping action of platelets — possibly preventing a heart attack or a stroke. However,
aspirin therapy should not be
for the prevention of heart attacks in people who haven't already had a heart attack, stroke or another cardiovascular condition.
- Small doses of aspirin can lower the risk of heart attack, but it doesn't appear
to cut the chances of dying from the disease.
- Aspirin is best known as a painkiller and is sometimes also taken to help bring down a fever. But daily low-dose (81mg) aspirin is used to make the
blood less sticky and can help to prevent heart attacks and stroke. Aspirin given shortly after a heart attack decreases the risk of death. Aspirin is often used long-term to
help prevent further heart attacks, ischaemic strokes, and blood clots in people at high risk. It may also decrease the risk of certain types of cancer, particularly colorectal cancer.
- Most strokes are caused by clots in the blood vessels of the brain but some are caused by bleeds. Because aspirin thins the blood, it can sometimes make the patient bleed more easily. Aspirin isn't safe for everyone. It can also cause indigestion and, more rarely, lead to stomach ulcers. Anybody who has been taking low-dose aspirin for a long time
is advised not to stop overnight as that may also cause problems. Elderly people in good health should not take an aspirin a day; a recent trial found no benefit
for healthy people over the age of 70, and the pills increased the risk of potentially fatal internal bleeding, and did not reduce their risk of heart problems or have any other benefits.
- Aspirin, often hailed as a "miracle drug," is an effective pain relief, fever reduction, and inflammation and has been linked to reduced risk of a
number of health conditions, including heart attack, stroke and cancer. Its active ingredient, acetylsalicylic acid, is a synthetic derivative of salicylic acid, which has been used for its medicinal properties for thousands of years.
However, it can cause side effects like gastrointestinal bleeding and stomach ulcers, especially with long-term use.
- Pain Relief: Aspirin is commonly used to alleviate headaches, muscle pain, toothaches, and other minor aches and pains.
- Anti-inflammatory: It helps reduce inflammation, making it useful for conditions like arthritis.
- Fever Reduction: Aspirin can help lower fever, providing relief during illnesses like the flu.
- Heart Health: Low-dose aspirin is often recommended for people at high risk of heart attacks or strokes, as it can help prevent blood clots.
- Cancer Prevention: Some studies suggest that aspirin may reduce the risk of certain types of cancer, although more research is needed.
- Aspirin can help prevent heart attacks in people with diabetes, especially because they’re at higher risk for cardiovascular events like heart attacks and strokes due to factors like high blood sugar, high blood pressure,
and cholesterol issues. A low daily dose (typically 81 mg) reduces the risk of these events by preventing blood clots, but it also raises the chance of bleeding—particularly in the stomach or brain. That’s why it’s strongly
recommended for people with diabetes who already have established cardiovascular disease (secondary prevention), but for those without a history of heart disease (primary prevention), doctors consider each person’s cardiovascular
and bleeding risk before prescribing it.
- Aspirin is recommended for some people with diabetes because they have a significantly higher risk of cardiovascular disease due to factors like chronic inflammation, high blood sugar, and increased clotting tendencies,
and aspirin—being an antiplatelet agent—helps by thinning the blood and reducing the chance of blood clots that can lead to heart attacks or strokes. It’s commonly used for secondary prevention in those who have already experienced
a cardiovascular event, and may also be considered for primary prevention in individuals over 50 with additional risk factors like high blood pressure or high cholesterol, as long as their risk of bleeding is low.
- For people with diabetes, aspirin can offer significant benefits—like reducing the risk of heart attacks and strokes by preventing blood clots, especially in those who’ve already had a cardiovascular event (secondary prevention)
or who are over 50 with additional risk factors such as high blood pressure or high cholesterol. However, it also carries notable risks, primarily the increased chance of serious bleeding in the stomach or brain, which is why it’s
not recommended for everyone. The benefit-risk balance is particularly narrow, with studies showing aspirin may prevent about one cardiovascular event per 100 people over seven years but also cause a major bleeding episode in roughly
the same number. As a result, aspirin use in diabetes should be tailored to the individual, based on their personal risk profile and under the guidance of a healthcare provider.
- Studies show that regular use of aspirin or other NSAIDs may reduce colorectal cancer risk by 20–30%, especially in individuals with higher baseline risk2. However, these medications can have side effects (like gastrointestinal bleeding),
so they should only be used preventively under medical guidance.
- People suffered from mild hypertension, which is a blood pressure reading of no higher than 160/100 mm Hg, took a 81-milligram tablet of aspirin in the evening had a significant reduction in their blood pressure. Those who took
the aspirin in the morning had no reduction at all.
- Taking aspirin after a cancer diagnosis has been linked to a roughly 20% improvement in survival, according to a large 2021 meta-analysis of 118 observational studies involving more than 250,000 patients with cancers such as colon,
breast, and prostate. This survival benefit is thought to stem from aspirin’s anti-inflammatory and anti-platelet effects, which may inhibit tumor growth and spread. However, since the data primarily comes from observational studies
rather than randomized controlled trials, causation hasn’t been definitively established. Moreover, more recent clinical trials, such as ASPREE and ASAC, have produced mixed results—particularly in older adults and those with
advanced cancer—highlighting that aspirin’s potential benefits must be carefully weighed against risks like gastrointestinal bleeding, and its use should be guided by medical professionals.
- Daily aspirin use has been linked to a lower risk of certain cancers, particularly colorectal cancer, with the most pronounced benefits seen in individuals at higher risk, such as those with Lynch syndrome—a genetic condition
that increases cancer susceptibility. Research shows that taking aspirin in high doses for at least two years can significantly reduce colorectal cancer incidence in these high-risk populations, and even low-dose aspirin (75–100 mg)
has demonstrated strong protective effects with fewer side effects. However, aspirin use isn't universally beneficial; it carries potential risks like gastrointestinal bleeding and may even increase cancer-related mortality in older
adults, as highlighted in studies like the ASPREE trial. Therefore, while aspirin may offer important preventive benefits, especially for those with elevated risk, its use for cancer prevention should be guided by individualized medical
advice.
- For individuals with rheumatoid arthritis (RA), taking a baby aspirin or a cholesterol-lowering statin may offer meaningful health benefits when used under medical supervision. Low-dose aspirin (81 mg) can provide cardiovascular
protection—especially important since RA patients have an elevated risk of heart disease—though long-term use carries risks like gastrointestinal bleeding. Statins, typically prescribed for lowering cholesterol, also possess
anti-inflammatory and immune-modulating properties that may help reduce RA progression and cardiovascular complications, with some studies suggesting a reduced RA incidence among users. However, any potential benefit must be
balanced with possible side effects, and treatment decisions should always be made in consultation with a healthcare provider.
- In addition to reducing the risk of heart attacks and strokes, aspirin has been found to lower the risk of colorectal cancer—the second most common cancer in developed countries after lung cancer—particularly when used
consistently over several years. Its protective effects are especially pronounced in individuals with cardiovascular conditions like heart disease or high blood pressure, as well as those who have already experienced a heart
attack or stroke. By inhibiting platelet aggregation, aspirin helps prevent blood clots and may also impede cancer-related inflammation and tumor growth. However, its use should be guided by a healthcare provider due to
the risk of side effects such as gastrointestinal bleeding.
- The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has seen almost 270 million confirmed
cases and over 5.2 million reported deaths worldwide as of December 2021. In November 2021, Food and Drug Administration (FDA) recommended authorization of the
molnupiravir pill made by Merck. When the drug enters the bloodstream,
it blocks the ability of the SARS-CoV-2 virus to replicate. This new pill is similar—in function to Tamiflu, the antiviral
medication that is used to prevent serious symptoms of flu. Many patients with COVID-19 recover from their acute infection with no or minimal medical intervention.
However, early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with COVID-19.
- Anticholinergic medications, which include those used for conditions, such as allergies (e.g.; Benadryl),
overactive bladder (e.g.; Ditropan),
depression (e.g.; doxepin) and
insomnia (e.g.; Sominex) may be associated with an
increased risk of pneumonia,
especially in older adults. Research indicates that these drugs may raise the risk by up to 59%, with the danger being particularly high during the initial 30 to 90 days of use. The elevated risk is likely due to side effects
such as sedation and impaired cognitive function, which can lead to swallowing difficulties or reduced respiratory defenses, thereby making lung infections more likely.
- The heartburn drug Nexium
cost $2,526,306,069 for 1,484,011 American Medicare patients, who filled 8,192,362 prescriptions
and refills in 2013. However, by 2023 and 2024, the financial landscape had shifted dramatically due to the widespread availability of generic esomeprazole and the transition of Nexium 24HR to over-the-counter status, which is generally
not covered by Medicare Part D. As a result, total Medicare spending on Nexium has dropped significantly, with the cost per generic esomeprazole prescription often ranging from $0 to $13, depending on individual plan coverage and stage,
reflecting broader trends in cost reduction for once-costly brand-name drugs.
- A large randomized controlled trial known as the Physicians' Health Study II found that taking a daily multivitamin modestly reduced the overall risk of cancer
in healthy middle-aged and older men. The study followed nearly 15,000 male physicians aged 50 and older for over a decade and reported an 8% reduction in total cancer incidence among those who took a daily multivitamin compared to those
who took a placebo. While the effect was modest and did not significantly impact prostate or colorectal cancer rates, it suggests that long-term multivitamin use may offer a small protective benefit against cancer in this population.
- Regular use of vitamin E supplements has been linked to an increased risk of developing prostate cancer, particularly in findings from the large-scale SELECT trial, which showed that men taking 400 IU of vitamin E daily faced
a 17% higher risk compared to those on a placebo. The elevated risk was especially notable in individuals with low selenium levels at the start of the study. Although earlier research hinted at possible protective effects,
later evidence reversed that belief, indicating that high-dose vitamin E supplementation may actually do more harm than good in this context. Consequently, experts advise against using vitamin E supplements for prostate cancer
prevention, emphasizing that such supplements should only be used under medical supervision when clearly indicated.
- Fish oil supplements, which are rich in omega-3 fatty acids like EPA and DHA, may help prevent some young people showing
early signs of mental illness from developing schizophrenia, a severe psychiatric disorder that typically begins in adolescence or early adulthood and affects about 2.4 million Americans. A study published in Nature Communications
found that high-risk individuals aged 13 to 25 who took fish oil daily for 12 weeks had a significantly lower chance of progressing to full-blown psychosis compared to those given a placebo. Researchers believe omega-3s may
support brain health by reducing inflammation and enhancing neural function, offering a potentially safe and accessible early intervention, especially when compared to antipsychotic medications, which often carry serious side effects.
While further studies are needed to confirm the protective effects and establish ideal dosing, this research offers hope for delaying or preventing schizophrenia in vulnerable youth.
- Several large studies, including the Iowa Women’s Health Study and more recent NIH-supported research, have shown that commonly used dietary supplements—such as multivitamins, vitamin B6, folic acid, iron, magnesium, zinc,
and copper—do not extend the lifespan of older women and may even be associated with a higher risk of death. Iron supplements, in particular, showed the strongest link to increased mortality, while calcium was the only supplement
tied to a reduced risk. These findings suggest that for well-nourished older adults, routine supplement use offers no longevity benefits and may carry health risks, emphasizing the importance of individualized guidance from
healthcare providers when considering supplement use.
- Studies on medication use in older adults suggest that up to 47% of prescriptions provided by doctors could potentially be discontinued without negatively impacting patients’ health, highlighting the widespread issue of polypharmacy.
Many of these medications may be redundant, inappropriate, or even harmful due to age-related changes in metabolism and increased sensitivity to drug interactions. This has fueled the growing practice of deprescribing, where
healthcare providers systematically review and reduce unnecessary medications to minimize side effects, improve quality of life, and lower the risk of complications such as falls, confusion, and hospitalizations.
- Taking the highest approved dose of simvastatin (80 mg) to lower cholesterol has been associated with a significantly increased risk of serious muscle damage, particularly a rare but life-threatening condition called rhabdomyolysis,
which can lead to kidney failure or even death. Because of this danger, the FDA advises that this dose should only be continued in patients who have already been using it for at least 12 months without any signs of muscle injury.
It is not recommended to start new patients on the 80 mg dose. Caution is especially important when simvastatin is taken alongside other medications that may increase the risk of muscle toxicity. In many cases, lower doses or
alternative statins provide a safer approach to managing high cholesterol.
- According to the World Health Organization, over half of all medicines worldwide are prescribed, dispensed, or sold inappropriately, and about 50% of patients do not take their medications correctly. This widespread issue—known
as irrational medicine use—can lead to serious consequences, including increased drug resistance, avoidable side effects, wasted healthcare resources, and poor health outcomes. Common examples include overprescribing antibiotics
for viral infections, using injections when oral medications would suffice, and failing to follow clinical guidelines. Addressing this challenge requires coordinated efforts in education, regulation, and patient engagement to
promote safer, more effective use of medicines.
- Some studies have suggested that taking calcium supplements may increase the risk of heart attacks, with some findings indicating an 86% higher risk among regular supplement users compared to non-users—particularly in
postmenopausal women taking high doses of supplemental calcium (around 1,000 mg/day). The suspected mechanism involves sudden spikes in blood calcium levels that could contribute to arterial plaque buildup. However, research
on this topic remains mixed; while certain studies raise concerns, others have found no clear link, and some even suggest a protective cardiovascular effect when calcium is taken alongside vitamin D. Experts generally agree
that calcium from food sources is safer, and decisions about supplementation should be based on individual health needs in consultation with a healthcare provider.
- Some studies have suggested that Calcium supplements (especially without vitamin D) may slightly increase
the risk of heart disease or
heart attack, particularly in postmenopausal women.
The theory is that large doses of supplemental calcium might cause spikes in blood calcium levels, potentially leading to arterial calcification over time. However, the evidence is mixed. Some meta-analyses have
found a modest increase in cardiovascular risk with supplements. Others found no significant link, especially when calcium is taken with vitamin D, which may help regulate calcium metabolism more safely.
Dietary calcium from food sources like dairy or leafy greens does not appear to carry the same risk.
- Some studies have suggested a possible link between high levels of Omega-3 fatty acids—particularly the long-chain types found in fish oil,
such as EPA and DHA—and an increased risk of prostate cancer. A notable example is a study from the SELECT trial,
which found that men with the highest blood levels of omega-3s had a 43% higher risk of developing prostate cancer compared to those with the lowest levels. However, the evidence is mixed: other large studies have found no
such association, and populations with high fish consumption, like Japanese men, tend to have lower prostate cancer mortality. Researchers caution that while omega-3s have well-established cardiovascular benefits, their role
in prostate cancer risk remains unclear and may depend on factors like dosage, source (supplements vs. food), and individual health profiles.
- Heart patients taking the popular blood-thinning drug
warfarin, which is an
anticoagulant, are risking potentially dangerous complications (e.g.; severe bleeding or a blood clot) by combining it with supplements, such as
fish oil,
coenzyme Q10,
glucosamine,
chondroitin, and
multivitamin. Combining warfarin with certain supplements—including fish oil, coenzyme Q10, glucosamine, chondroitin, and multivitamins—can pose serious
risks for heart patients due to potential interactions that affect blood clotting. Fish oil, glucosamine, and chondroitin may enhance warfarin's blood-thinning effect, increasing the risk of bleeding, while coenzyme Q10 and
some multivitamins (especially those containing vitamin K) may reduce its effectiveness, raising the risk of blood clots. Because warfarin has a narrow therapeutic window, even small changes in clotting balance can lead to dangerous
outcomes. Patients on warfarin should always consult their healthcare provider before starting or stopping any supplement to ensure safe and effective anticoagulation management.
- Regular use of the painkiller ibuprofen may help lower the risk of developing Parkinson's disease, according to several studies. One notable investigation from the Harvard School of Public Health found that individuals
who took ibuprofen at least twice a week had a 38% lower risk of developing Parkinson’s compared to non-users. This protective effect is thought to stem from ibuprofen's ability to reduce brain inflammation, a factor believed
to contribute to the disease. Interestingly, this benefit appears unique to ibuprofen, as other NSAIDs like aspirin did not show similar results. However, while these findings are encouraging, they do not confirm a direct
cause-and-effect relationship, and long-term ibuprofen use can lead to side effects such as gastrointestinal bleeding. Therefore, anyone considering ibuprofen for preventive purposes should first consult a healthcare provider.
- Blood-thinning medications like aspirin, warfarin (Coumadin), and clopidogrel (Plavix) are widely used to prevent strokes and other clot-related conditions by reducing
the blood’s ability to form clots. However, this same mechanism also makes it easier for small blood vessels under the skin to break and leak, leading to increased bruising—even from minor bumps or injuries2. This is a common and expected
side effect, especially in older adults or those taking multiple medications. While some bruising is normal, sudden, large, or unexplained bruises should be discussed with a healthcare provider to rule out more serious bleeding issues.
- Combining Plavix (clopidogrel), which is used to prevent blood clots after a recent heart attack or stroke, with aspirin, which helps lower the risk of clot formation in the heart and brain, can offer protective benefits in
certain high-risk patients but also carries significant risks. Known as dual antiplatelet therapy (DAPT), this combination is often prescribed after stent placement, acute coronary syndromes, or minor strokes to reduce the
chance of another clot-related event. However, the regimen markedly increases the risk of serious bleeding, including gastrointestinal and brain hemorrhages, and may be harmful for individuals without substantial coronary artery disease.
Because of these risks, DAPT should only be used under close medical supervision and for a clearly defined duration tailored to the patient’s specific condition.
- Tranexamic acid (TXA) is an affordable and highly effective medication that helps control hemorrhage by preventing the breakdown of blood clots, making it a lifesaving treatment in trauma care. Research, including
the pivotal CRASH-2 trial, has shown that when TXA is administered promptly—ideally within the first hour after injury—it can reduce trauma-related mortality by up to one-third. Experts estimate that widespread, early use of
TXA could save more than 100,000 lives globally each year, particularly in regions with limited access to advanced trauma care. Innovations like intramuscular delivery are also expanding its use beyond hospital settings, enabling
faster treatment by first responders.
- Proton pump inhibitors (PPIs) like Nexium,
Prilosec, and
Prevacid—commonly used to treat frequent heartburn—have been linked to an increased risk of fractures in the hip, spine, and wrist, particularly when taken at
high doses or for a year or more. The FDA has issued safety communications noting that these medications may interfere with calcium absorption by reducing stomach acid, which is essential for breaking down calcium salts into absorbable forms.
This can lead to decreased bone mineral density over time, especially in older adults, raising the risk of osteoporosis-related fractures. While the risk appears to be lower with short-term or low-dose use, healthcare providers are
encouraged to weigh the benefits and risks carefully and consider the lowest effective dose for the shortest duration necessary.
- Roughly 4% of U.S. adults aged 20 and older use prescription sleep aids, yet surprisingly, only about one in six adults with a diagnosed sleep disorder and one in eight adults who report trouble sleeping actually use them.
This gap highlights a disconnect between sleep challenges and treatment, possibly due to concerns about side effects, dependency, or a preference for non-pharmacological approaches like cognitive behavioral therapy or lifestyle changes.
- Statins, widely prescribed to lower cholesterol, are highly effective in preventing heart attacks and strokes—especially in older adults with high blood pressure
or other cardiovascular risk factors. Beyond their heart-protective effects, some research suggests that statins may also slow aspects of biological aging
by reducing inflammation and protecting against telomere shortening, a key marker of cellular aging. However, certain statins—particularly at higher doses—have been associated with a modestly increased risk of developing type 2 diabetes,
likely due to their impact on insulin sensitivity and glucose metabolism. Despite this, experts agree that for most patients at risk of cardiovascular disease, the benefits of statins far outweigh the potential risk of diabetes,
making them a cornerstone of preventive therapy.
- Statins may raise risk for nuclear sclerotic cataract,
and may also raise risk for type 2 diabetes. The statins affected included:
Altoprev (lovastatin extended-release),
Crestor (rosuvastatin),
Lescol (fluvastatin),
Lipitor (atorvastatin),
Livalo (pitavastatin),
Mevacor (lovastatin),
Pravachol (pravastatin), and
Zocor (simvastatin).
Products containing statins in combination with other drugs include:
Advicor (lovastatin/niacin extended-release),
Simcor (simvastatin/niacin extended-release), and
Vytorin (simvastatin/ezetimibe).
- Statins, widely used to lower cholesterol, frequently
cause muscle pain and joint aches—symptoms that typically manifest as soreness, weakness, or fatigue in
large muscle groups such as the thighs, shoulders, or hips. While clinical trials suggest these side effects occur in about 5% of users, real-world data indicates the rate could be as high as 30%, potentially influenced by the nocebo effect,
where negative expectations amplify perceived discomfort. The likelihood of experiencing these symptoms may be higher among older adults, women, and those on high doses or certain statin types like simvastatin or atorvastatin.
Fortunately, these effects can often be managed by adjusting the dosage, switching statins, or exploring non-statin alternatives under a healthcare provider’s guidance.
- Research has shown that patients who took VioxxVioxx (rofecoxib), a COX-2 inhibitor once used to treat arthritis and pain, faced a significantly
increased risk of cardiovascular events—including blood clots—even after stopping the drug. A follow-up analysis of clinical trial data
found that during the year after discontinuation, patients previously on Vioxx experienced twice as many cardiovascular thromboembolic events and more than double the number of deaths compared to those who had taken a placebo.
This lingering risk remains poorly understood, but it underscores the long-term impact certain medications can have on heart health, even after they’re no longer being used.
- Medications commonly used to treat high blood pressure and heart disease—such as ACE inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers, diuretics, and statins—have been associated with a reduced risk of
dementia and Alzheimer’s disease. Studies suggest these drugs may lower the risk by 12% to 25%, depending on the specific medication and how long it’s used. For instance, research from the National Institute on Aging found that
effectively managing hypertension decreased the risk of dementia by 12% and Alzheimer’s by 16%. Similarly, long-term use of cardiovascular medications in Swedish studies showed a significant drop in dementia rates, particularly when
multiple drugs were used in combination. Statins, in particular, appear to offer added protection against cognitive decline, especially in patients with heart failure.
- Atorvastatin, sold under the brand name Lipitor, has been linked to a modestly increased risk of developing type 2 diabetes, particularly at higher doses or in individuals already predisposed to the condition.
Studies suggest that statins like atorvastatin may interfere with insulin sensitivity and elevate blood sugar levels over time, prompting the FDA in 2012 to issue a warning about this potential side effect. Despite this risk,
health experts widely agree that the cardiovascular benefits of atorvastatin—especially in people with elevated cholesterol or existing heart disease—generally outweigh the risk of diabetes. Physicians may monitor blood glucose
levels during treatment and, when needed, adjust the therapy or explore statins with a lower risk profile.
- Aromatase inhibitors, including drugs like anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin), are a class of medications
commonly used in postmenopausal women with hormone receptor-positive breast cancer to prevent new or recurring tumors. By blocking the enzyme aromatase, which converts androgens to estrogen in peripheral tissues, these drugs
effectively lower estrogen levels, thereby inhibiting the growth of estrogen-dependent cancers. Clinical trials have shown that aromatase inhibitors are more effective than tamoxifen in reducing the risk of recurrence, and
they may also be used preventively in women at high risk for breast cancer. Although effective, they can cause side effects such as joint pain, hot flashes, and bone thinning, which is why doctors often monitor bone density
and personalize treatment plans based on the patient’s risk profile.
- People take tricycle antidepressants raise a higher risk of cardiovascular disease. Tricyclic antidepressants (TCAs), such as amitriptyline, nortriptyline, and imipramine, have been associated with a higher risk of
cardiovascular complications, particularly in individuals with existing heart conditions. These medications can disrupt cardiac function by causing orthostatic hypotension, arrhythmias, and conduction abnormalities, especially
at high doses or in cases of overdose. TCAs may also impair the heart's ability to contract efficiently and have been linked to worsening ischemic heart disease and even sudden cardiac death. As a result, they are generally
avoided in patients with coronary artery disease or significant arrhythmias, and newer antidepressants like SSRIs are typically preferred for those with cardiovascular risk due to their safer cardiac profile.
- Avandia (rosiglitazone), a once-popular diabetes medication, became highly controversial after studies linked it to an increased risk of serious
cardiovascular events—including heart attacks, strokes, heart failure, and deaths—with estimates suggesting it may have contributed to as many as 100,000 such cases in the U.S. since its approval. In 2010, European regulators
removed the drug from the market, citing safety concerns, while the U.S. FDA imposed strict restrictions that limited its use to select patients through a special access program. Although those restrictions were lifted in 2013
after a re-evaluation of the data, Avandia's reputation suffered irreparable damage, and it is now rarely prescribed, with most healthcare providers favoring safer alternatives.
- Avandia (rosiglitazone), a controversial drug once widely used to treat type 2 diabetes, has been linked to an increased risk of serious health issues,
including heart attacks, congestive heart failure, and cardiovascular-related death. Beyond its cardiovascular risks, Avandia has also been associated with a higher incidence of bone fractures—particularly among women over 65—and
vision loss due to diabetic macular edema, a condition characterized by swelling in the retina that can lead to blindness. As a result of these significant safety concerns, Avandia’s use has been dramatically restricted and is now
generally reserved for patients who cannot adequately manage their diabetes with other, safer medications.
- Topamax (topiramate), an anticonvulsant used to treat epilepsy and migraines, has been linked to an increased risk of oral birth defects
such as cleft lip and cleft palate when taken during pregnancy, especially in the first trimester—often before a woman knows she's pregnant. The risk is higher when used at higher doses for epilepsy compared to migraine prevention.
Due to these findings, the FDA reclassified Topamax as a Pregnancy Category D medication, indicating confirmed evidence of risk to human fetuses. Women of childbearing age who are prescribed Topamax are strongly advised to
use reliable contraception and discuss safer alternatives with their healthcare provider if pregnancy is a possibility.
- Taking opioid painkillers such as codeine, hydrocodone, and oxycodone shortly before or during
early pregnancy has been linked to an increased risk of congenital birth defects, particularly involving the heart, brain, and spine. Research reviewed by the FDA and CDC indicates that opioid exposure during the first trimester
may interfere with fetal development, leading to conditions like congenital heart defects, neural tube defects, and gastroschisis—a serious abdominal wall defect. Because many women may not realize they’re pregnant during
this critical window, healthcare providers are urged to carefully weigh the risks and benefits of prescribing opioids to women of childbearing age and to discuss effective contraception and alternative pain management strategies
when appropriate.
- In 2024, the United States saw a dramatic improvement in the overdose crisis, with drug overdose deaths dropping to an estimated 80,391—a 26.9% decline from the 110,037 recorded in 2023 and the lowest total since 2019.
Opioid-related fatalities fell sharply, from about 83,140 in 2023 to 54,743 in 2024, marking a 37% reduction, while deaths involving synthetic opioids like fentanyl, though still prevalent, also declined significantly.
Overdose deaths tied to methamphetamine and cocaine dropped by 20–28%, and nearly every state reported progress, with places like Virginia, Ohio, and West Virginia experiencing declines of 35% or more.
- Studies have shown that patients who took Vioxx (rofecoxib), a COX-2 inhibitor once used to treat arthritis and pain, faced a significantly
elevated risk of cardiovascular events—including blood clots and death—even after stopping the medication. A follow-up analysis of clinical trial data found that during the off-drug period, patients previously treated
with Vioxx experienced twice as many cardiovascular thromboembolic events and more than double the number of deaths compared to those who had taken a placebo. This lingering risk remains poorly understood, but it underscores
the long-term cardiovascular impact of certain medications, even after discontinuation.
- A study suggests that individuals who take cholesterol-lowering statins for one to two years or longer may face a reduced risk of developing gallstones, particularly those composed of cholesterol. Statins lower blood
cholesterol by inhibiting its production in the liver and also decrease cholesterol secretion into bile—a key contributor to gallstone formation. One large population-based study found that people who had filled 20 or
more statin prescriptions were significantly less likely to develop gallstone disease than non-users. A separate systematic review further supported this link, showing that medium- to long-term statin use was associated
with a lower risk of both gallstones and gallbladder removal (cholecystectomy). While study results differ slightly, the overall evidence suggests that statins may offer a protective benefit against cholesterol-based gallstones.
- Zantac and its generic form, ranitidine, the heartburn pill that once ranked as the world's best-selling drug,
contained a chemical N-nitrosodimethylamine (NDMA) that
causes cancer. The Food and
Drug Administration confirmed unacceptable levels of this chemical,
in Zantac. The FDA's testing suggests
Pepcid,
Tagamet,
Nexium,
Prevacid and
Prilosec do not contain this chemical. More than 40 other countries from Australia to
Vietnam have also either stopped sales of Zantac and its generic pills, launched investigations or otherwise
stepped in to protect consumers from possible health risks.
- Zocor (simvastatin), a cholesterol-lowering statin, has been associated with serious side effects—particularly when taken at the high 80 mg dose. While effective at reducing LDL cholesterol, this dosage has been
linked to an increased risk of muscle injury, including a rare but life-threatening condition called rhabdomyolysis, which can lead to severe kidney damage or even death. Due to these risks, the U.S. FDA has recommended that
the 80 mg dose should not be started in new patients and should only be continued in those who have been taking it for over a year without complications. Most patients can achieve similar cholesterol-lowering benefits with
lower doses or alternative statins that carry a lower risk of muscle toxicity.
- When combined with radiation therapy, the chemotherapy drug cisplatin has been shown to improve survival outcomes in certain cervical cancer patients,
particularly those with advanced-stage disease. For example, a clinical trial involving women with stage IIIB squamous cell carcinoma of the cervix found that adding weekly cisplatin to radiotherapy reduced the risk of death by
about 19% compared to radiation alone. However, more recent data from the 2025 Society of Gynecologic Oncology Annual Meeting revealed that in cases of intermediate-risk, early-stage cervical cancer, cisplatin offered no significant
survival benefit and was associated with more severe side effects. These findings suggest that while cisplatin-based chemoradiotherapy can enhance survival in specific high-risk groups, its effectiveness and tolerability depend heavily
on individual cancer stage and risk profile.
- The Nitrosodimethylamine (NDMA) is an
environmental contaminant found in water along with meat, dairy, and vegetables.
Exposure to high amounts of NDMA can increase the risk of bladder, stomach,
gastric or colorectal cancers. The
heartburn drug Zantac has high levels of NDMA above the Food and Drug Administration (FDA)'s acceptable daily limit, causing cancer danger.
The FDA issued the order to remove from the market all prescription and over-the-counter (OTC) ranitidine medications sold under the brand name Zantac
(tablets or liquid) after concluding that the cancer-causing contaminant NDMA can build up in the drug when stored at higher than room temperatures for long periods. Many heartburn products (brand and generic forms) that do not contain NDMA, such as Pepcid,
Tagamet, Nexium, Prevacid and
Prilosec, can replace Zantac.
- A number of medications have been linked to the development or worsening of tinnitus due to their ototoxic effects, which can damage the inner ear or auditory nerves.
These include certain antibiotics like polymyxin B, erythromycin, vancomycin, and neomycin; cancer treatments such as mechlorethamine and vincristine; loop diuretics like bumetanide, ethacrynic acid, and furosemide; and quinine-based drugs
used for malaria or other conditions. Additionally, antidepressants, both tricyclics and SSRIs, have been reported to trigger tinnitus in some individuals, while high-dose aspirin and NSAIDs are among the most frequently implicated,
though symptoms often subside after discontinuation. The risk depends on dosage, duration, and individual susceptibility, so medical consultation is recommended for anyone experiencing tinnitus while taking these medications.
- Vaccines prevent diseases that can be dangerous, or even deadly. Vaccines greatly reduce the risk of infection
by working with the body’s natural defenses to safely develop immunity to disease. When germs, such as bacteria or viruses, invade the body, they attack and multiply. This invasion, called an infection, is what causes illness. The immune system uses several tools to fight infection.
Blood contains red blood cells, for carrying oxygen to tissues and organs, and white or immune cells, for fighting infection. The first time the body encounters a germ, it can take several days to make and use all the germ-fighting tools needed to get over the infection. After the infection,
the immune system remembers what it learned about how to protect the body against that disease. Vaccines help develop immunity by imitating an infection. Once the imitation infection goes away, the body is left with a supply of “memory” that will remember how to fight that disease in the future.
- FDA warned patients not to combine Plavix
with
- Some research suggests that calcium supplements—especially when taken without vitamin D—may increase the risk of heart attacks, with one pooled analysis reporting a 30% higher incidence of cardiovascular events among people
over 40 who used calcium pills compared to those who didn’t. The suspected mechanism involves elevated blood calcium levels potentially promoting arterial calcification and plaque formation. Although calcium supplements are often
taken to support bone health, the evidence around their effectiveness and safety is mixed; some studies show limited benefit in fracture prevention, while others suggest added risks. Experts generally recommend obtaining calcium
through dietary sources, such as dairy products and leafy greens, which are believed to be both safer for the heart and more beneficial for overall skeletal health.
- The Nitrosodimethylamine (NDMA) is an
environmental contaminant found in water along with meat, dairy, and vegetables.
Exposure to high amounts of NDMA can increase the risk of bladder,
stomach,
gastric or
colorectal cancers. The
heartburn drug Zantac has high levels of NDMA above the Food and Drug Administration
(FDA)’s acceptable daily limit, causing cancer danger. The FDA issued the order to remove
from the market all prescription and over-the-counter (OTC) ranitidine medications sold under the brand name Zantac (tablets or liquid) after concluding that the cancer-causing contaminant NDMA can build up in the drug when stored at
higher than room temperatures for long periods. Many heartburn products (brand and generic forms) that do not contain NDMA, such as Pepcid,
Tagamet, Nexium,
Prevacid and
Prilosec, can replace Zantac.
- Inhalers were developed from the late 1700s to deliver medication into the body through inhalation, or breathing through the mouth.
Inhalers were associated with lung complaints, but during the 20th century they became connected with asthma treatment.
Asthma inhalers are hand-held, portable devices that deliver medication to your lungs. Each consist of a pressurized
canister containing medication that fits into a boot-shaped plastic mouthpiece. With most metered dose inhalers, medication is released by pushing the canister into the boot.
- Medicines reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes; however, medicines can also cause unwanted reactions.
One problem is interactions, which may occur between
- Topical benzocaine—commonly used for alleviating itching, toothaches, and minor skin irritations—has been linked in rare
instances to a serious condition called methemoglobinemia, which reduces the blood’s capacity to carry oxygen. This can lead to a bluish discoloration of the lips, fingertips, or other extremities and may be accompanied
by symptoms such as shortness of breath, fatigue, dizziness, confusion, or even loss of consciousness. Alarmingly, this reaction can occur even after a single application, particularly when benzocaine is used in high doses or on
broken skin. Given these risks, the U.S. Food and Drug Administration (FDA) has issued strong warnings, especially advising against the use of benzocaine-containing products in children under two years of age unless specifically
directed by a healthcare provider. Prompt medical attention is essential
if any signs of methemoglobinemia appear.
- The CAPRISA 004 trial marked a groundbreaking advancement in HIV prevention by demonstrating that a vaginal gel containing 1% tenofovir—an antiretroviral drug—could significantly reduce infection risk among women.
Conducted in South Africa between 2007 and 2009, the two-and-a-half-year study involved 900 participants and showed that using the gel before and after sex lowered HIV acquisition by 39%, with efficacy rising to 54%
among women who used it consistently. It also reduced genital herpes infections by 51%. These results, presented at the 2010 International AIDS Conference, were hailed as a milestone for female-controlled prevention strategies,
although follow-up studies like FACTS 001 yielded mixed outcomes due to challenges with adherence. Nonetheless, CAPRISA 004 remains a pivotal achievement in empowering women to protect themselves in high-risk settings.
- Zantac and its generic form, ranitidine, the heartburn pill that once ranked as the world’s best-selling
drug, contained a chemical N-nitrosodimethylamine (NDMA) that
causes cancer. The
Food and Drug Administration confirmed unacceptable levels of this chemical,
in Zantac. The agency’s testing suggests
Pepcid,
Tagamet,
Nexium,
Prevacid and
Prilosec do not contain this chemical. More than 40 other countries from Australia to
Vietnam have also either stopped sales of Zantac and its generic pills, launched investigations or
otherwise stepped in to protect consumers from possible health risks.
- Zolgensma, a new drug approved by the FDA in May 2019, costs more than $2.1 million. It's made by AveXis, a
drugmaker owned by pharmaceutical giant Novartis. This gene therapy medication used to treat rare spinal muscular atrophy in children less than two. This drug, which is given once by injection into a vein, is now the most
expensive drug on the market.
- Luxturna, an Spark Therapeutics' AAV vector-based one-time gene therapy, is used for the treatment of confirmed biallelic RPE65 mutation-associated retinal dystrophy,
an inherited retinal disorder that leads to vision loss. The gene therapy drug is priced at $425,000 per eye for a total cost of $850,000 per patient.
- Myalept is used to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy. Patients typically
use 14 vials per month and each vial is priced at $4,633, the drug costs $778,344 per year.
- A new study raises fresh concerns about Zetia and its cousin, Vytorin.
Zetia failed to shrink buildups in artery walls, and Zetia users also suffered more heart attacks. Vytorin is a pill that combines Zetia with a
statin. It has been proven that neither Vytorin nor Zetia are any better at lowering cholesterol, reducing plaque buildup in the arteries, or prevent
heart attacks or death than low grade niacin.
- Aurobindo Pharma USA's Folotyn is used for the treatment for peripheral T-cell
lymphoma, on the basis of a clinical trial demonstrating the ability to reduce tumor size, but not to prolong life. The drug costs $30,000
a month or more, which could reach a total of $126,000 during a course of treatment.
- Monthly costs for the drugs for patients with advanced cancer ranged from $5,454 to $45,004, and the average was $13,176;
between 2006 and 2015 the average monthly cost of oncology drugs increased from $7,103 to $15,535, and the incremental cost of new drugs increased from $30,447 to $161,141. From 2016 to 2024, the cost of oncology drugs in the U.S. continued
to climb sharply, with monthly expenses for advanced cancer treatments ranging from $13,000 to over $25,000 and annual costs of newly launched drugs often exceeding $260,000. The median monthly price rose steadily, reaching an estimated
$25,000 or more by 2024, while the incremental cost of new oncology therapies soared from $115,000 to $300,000 annually. Spending on cancer drugs increased from $58 billion in 2018 to $88 billion in 2022 and is projected to
surpass $100 billion by 2025. Although new policies like Medicare’s out-of-pocket caps have offered some financial relief, the escalating costs reflect a trend toward more complex and targeted therapies, raising concerns about
affordability and access for patients nationwide.
- Poisoning is the leading cause of injury-related mortality in the United States, with more than 40,000 deaths annually. Drugs account for 90% of poisoning
deaths, and the number of deaths from drug poisoning has increased substantially. An estimated 1.1 million emergency department visits for drug poisoning were made each year, comprising 2.4% of total injury-related visits. Among
persons aged 35–49, the emergency department visit rate for drug poisoning was higher among females(51.2 per 10,000 persons) compared with males (31.9 per 10,000 persons).
- 90% of more than 100 drugs, both prescription and over-the-counter, were perfectly good to use even 15 years after
the expiration date. Excluding certain prescription medicines such as nitroglycerin, insulin, and liquid antibiotics, most medicines stored under reasonable conditions retain at least
70% to 80% of their original potency for at least 1 to 2 years after the expiration date,
even after the container has been opened. The expiration date doesn't really indicate a point at which the medication is no longer effective or has become unsafe to use; expired medicine is safe to take, even those that expired years ago.
- Women who take acetaminophen during pregnancy
are more likely to have a hyperactive child.
Hyperactive behavior (called attention deficit hyperactivity disorder - ADHD) usually refers to constant activity, being easily distracted, impulsiveness,
inability to concentrate, aggressiveness, and similar behaviors.Kids with ADHD have problems paying attention and sitting still in their seats, and they do things without thinking about the results. Hundreds of over-the-counter and
prescription medications contain acetaminophen
- Popular heartburn medications known as Proton Pump Inhibitors (PPIs)—including omeprazole (Prilosec), esomeprazole (Nexium), and lansoprazole (Prevacid)—have been tied to a range of potential health issues when used long term,
including serious kidney damage, bone fractures, and an increased risk of dementia. Prolonged PPI use has been linked to chronic kidney disease and even end-stage renal failure, especially in older adults, as well as a higher
likelihood of hip, wrist, and spine fractures due to reduced calcium absorption. Some observational studies have also suggested a possible connection between PPIs and cognitive decline, potentially related to impaired
vitamin B12 absorption. More recent research has raised additional concerns about increased risks of cardiovascular events, hypertension, and electrolyte imbalances with extended use, prompting recommendations to take
the lowest effective dose for the shortest duration necessary and to consider alternatives like H2 blockers or lifestyle changes when appropriate.
- Drug overdoses killed 63,632 Americans in 2016. Nearly two-thirds of these deaths (66%) involved a prescription or illicit opioid. Overdose deaths increased in all categories of drugs examined for men and women,
people ages 15 and older, all races and ethnicities, and across all levels of urbanization. Some 32.4 million people - or 0.7 per cent of the world's adult population - are users of pharmaceutical opioids and opiates
such as heroin and opium. In 2023 and 2024, the United States saw a significant downturn in drug overdose deaths, reversing a long-standing upward trend. Estimated fatalities dropped from 107,543 in 2023 to approximately
80,391 in 2024—a 26.9% decline and the lowest total since 2019. While opioids remained the leading cause, accounting for around 60% of all overdose deaths, the number of fatalities involving synthetic opioids like fentanyl
fell by 37%, and deaths related to cocaine and methamphetamine also declined by 28% and 21%, respectively. Experts attributed this progress to expanded access to naloxone, improved treatment availability, and strengthened
harm reduction strategies. Globally, however, opioid use continues to pose a major challenge; the UNODC reported that around 60 million people used opioids in 2022, making them the second most-used drug class after cannabis,
with only one in eleven people with substance use disorders receiving adequate treatment.
- From 1991 to 2011, there was a near tripling of opioid prescriptions dispensed by U.S. pharmacies
from 76 million to 219 million
prescriptions; Mexican heroin production increased from an estimated 8 metric tons in 2005 to 50 metric tons in 2009 - more than a six-fold increase in just 4 years.
Pooling data from 2002 to 2012,
the incidence of heroin initiation was 19 times higher among those who reported prior nonmedical pain reliever use than among those who did not. Between 2013 and 2024, the United States saw a notable decline in opioid prescriptions,
which fell from roughly 219 million in 2011 to about 125 million by 2023, reflecting tighter regulations and growing awareness of addiction risks. Meanwhile, Mexican heroin production surged, climbing from 26 metric tons
in 2013 to an estimated 72 metric tons in 2021, driven by increased opium poppy cultivation before tapering as fentanyl grew to dominate the illicit drug market. Throughout this period, heroin initiation remained strongly
linked to prior nonmedical use of prescription opioids, with studies suggesting individuals who misused prescription pain relievers faced up to a 40-fold increased risk of developing heroin dependence. This era marked
a shift from a prescription-driven opioid crisis toward a more complex epidemic fueled by heroin and synthetic opioids like fentanyl.
- Ecstasy is a psychoactive drug used primarily as a recreational drug; it is often
mixed with a variety of substances such as LSD, cocaine,
amphetamine, meth, heroin, rat poison, caffeine, dog deworming substances and more. Ecstasy increases the release and slows the reuptake of the neurotransmitters serotonin, dopamine, and norepinephrine in parts of the brain;
it has stimulant and psychedelic effects; the initial increase is followed by a short-term decrease in the neurotransmitters; Ecstasy is use is illegal, highly addictive and incredibly dangerous.
- Prescription drug misuse has become a large public health problem, because misuse can lead to addiction, and even overdose deaths.
- Opioids:
Happy Pills,
Hillbilly Heroin,
OC,
Oxy,
Oxycotton,
Percs, and
Vikes.
- Depressants:
A-minus,
Barbs,
Candy,
Downers,
Phennies,
Reds,
Red Birds,
Seeping Pills,
Tooies,
Tranks,
Yellow Jackets,
Yellows, and
Zombie Pills.
- Stimulants:
Bennies,
Black Beauties,
Hearts,
Roses,
Skippy,
The Smart Drug,
Speed,
Vitamin R, and
Uppers (Cocaine, Amphetamines, and Methamphetamine).
- Three kinds of prescription drugs that are commonly abused are:
- Opioids—painkillers like Vicodin, OxyContin, or codeine
- Depressants—like those used to relieve anxiety or help a person sleep, such as Valium or Xanax
- Stimulants—like those used for treating attention deficit hyperactivity disorder (ADHD), such as Adderall and Ritalin
- Combining opioid pain or cough medications with benzodiazepines can lead to serious and potentially fatal outcomes, prompting the U.S. Food and Drug Administration (FDA) to issue a Boxed Warning—its most stringent safety
alert—for both classes of drugs. This combination significantly depresses the central nervous system and may result in extreme sedation, respiratory depression, coma, or death, even at low doses. Studies have shown that
individuals prescribed both drug types are up to ten times more likely to die from an overdose compared to those using opioids alone. As a result, the FDA strongly advises against co-prescribing these medications unless
absolutely necessary, recommending the lowest effective doses for the shortest possible duration and urging patients and caregivers to watch for signs of overdose—such as severe drowsiness, slow breathing, or unresponsiveness—and
to seek emergency medical help if they occur.
- According to the most recent data from the National Survey on Drug Use and Health (NSDUH), approximately 20 million Americans aged 12 and older reported using an illicit drug in the past month—a figure that underscores the
persistent scale of substance use in the U.S. The economic burden of drug abuse remains staggering, with total costs exceeding $190 billion annually, including $130 billion in lost productivity, $20 billion in healthcare
expenses, and $40 billion in legal and criminal justice costs. Among substances, marijuana continues to be the most commonly used illicit drug,
followed by cocaine, heroin,
inhalants, LSD (acid),
MDMA (ecstasy), methamphetamine,
PCP, anabolic steroids, and prescription medications like Vicodin and
OxyContin, which are often misused for their opioid effects. These trends highlight the need for sustained investment in prevention, treatment,
and education to address both the human and economic toll of drug misuse.
- In 2014, roughly 576,000 Americans spent more than $50,000 a year on prescription drugs alone. By 2021, that trend had grown dramatically, with the top 1% of healthcare spenders averaging $166,980 annually and the top 5%
around $71,067—figures that include all medical expenses, not just medications. With the continued surge in prices for specialty drugs used to treat cancer, autoimmune conditions, and other complex diseases, it's highly likely that in 2024,
hundreds of thousands of Americans are still spending over $50,000 each year on prescriptions, particularly those managing chronic or high-cost illnesses.
- In 2014, over 500,000 Americans spent more than $50,000 annually on prescription drugs, with 100,000 exceeding $100,000—a near-tripling from the year before. While updated figures for 2023–2024 aren't available, U.S. prescription
drug spending soared to $722 billion in 2023, up 13.6% in one year—the largest spike in two decades. This growth is driven by costly treatments for chronic and complex conditions, such as Ozempic, Humira, and Keytruda. Given these trends,
it's likely that hundreds of thousands still fall into these high-cost groups, representing a small but financially significant slice of the population.
- From 1998 to 2014, 75 of 78 investigational brain tumor drugs failed in clinical trials, and over the past 30 years, only 4 drugs and one device received FDA approval. Between 2015 and 2024, drug development remained difficult,
especially for aggressive tumors like glioblastoma, but a few important breakthroughs emerged. Approvals of vorasidenib, belzutifan, tovorafenib, trametinib, dabrafenib, and eflornithine marked progress in targeted therapies.
While overall success rates remain low, innovation is gaining ground through advances in immunotherapy, blood-brain barrier disruption, and precision medicine.
- Misusing prescription drugs—by taking medications not prescribed to you or using them in ways not directed by a doctor—can be extremely dangerous and even fatal. Prescription drugs are among the most commonly abused substances
in the U.S., with around 52 million people—roughly 18.4% of the population aged 12 and older—having misused them at least once. Although they once ranked just behind alcohol and marijuana, recent data places them fifth, following alcohol,
tobacco, marijuana, and cocaine. Commonly misused prescription drugs include opioids, sedatives, and stimulants, and despite their legitimate medical use, misuse can quickly lead to addiction, overdose, or death.
- As of today, roughly 16.3 million Americans aged 12 and older misuse prescription drugs each year,
and about 4% of youth aged 12–17 report doing so, though older estimates suggested that 2,500 teens tried pain relievers for the first time daily. Rural communities face unique risks due to easier access to medications and fewer resources
for treatment. While opioids remain the leading cause of overdose deaths, recent data show they’re involved in about 80% of all drug overdose fatalities, far surpassing other substances like cocaine or methamphetamine. Although
antidepressants and sedatives are also misused, the claim that they collectively account for more overdose deaths than all illicit stimulants combined is outdated and not supported by current CDC data.
- As of 2023 through 2025, the FDA's warning about the risk of hepatitis B virus (HBV) reactivation in patients treated with direct-acting antivirals (DAAs) for hepatitis C remains in effect, with no major updates since the initial
safety communication in 2016. The Boxed Warning still appears on DAA medications like Sovaldi and Mavyret, advising healthcare providers to screen all patients for current or past HBV infection and monitor them during and after treatment
to detect any signs of reactivation, which can lead to serious liver injury, including liver failure or death. Although no significant new outbreaks have been reported, the persistence of this warning underscores the importance of careful
screening and close monitoring when treating HCV with DAAs.
- The FDA has issued a strong warning about the risk of hepatitis B virus (HBV) reactivation in patients receiving direct-acting antivirals (DAAs) for hepatitis C. In some individuals with current or past HBV infection, starting
DAA therapy led to HBV reactivation—sometimes within 4 to 8 weeks—which can result in serious liver damage or even death. Between 2013 and 2016, the FDA documented 24 such cases, including two fatalities and one liver transplant,
prompting a Boxed Warning—the agency’s most serious alert—on several DAA medications. As a result, healthcare providers are urged to screen patients for HBV before initiating treatment and to monitor closely during and after
therapy to manage any potential reactivation.
- Wells Pharmacy Network issued a voluntary nationwide recall of all sterile products produced between February 22 and September 16, 2016, due to concerns raised by the U.S. Food and Drug Administration (FDA) over a lack
of sterility assurance2. Although no specific products were found to be contaminated and no adverse events were reported, the recall was initiated out of an abundance of caution. The affected items—over 600 in total—included
injectable solutions such as progesterone, testosterone, and gonadotropin, and spanned both human and veterinary use. The FDA emphasized that administering a product intended to be sterile, if contaminated, could result in
serious or life-threatening infections. Patients and providers were advised to discontinue use, quarantine any unused products, and contact the pharmacy for return instructions.
- The prices of cold-sore cream Denavir,
cancer drug Nilandron, beta blocker Dutoprol, and osteoporosis treatment
Miacalcin jumped 372 percent, 989 percent, 1,057 percent, and 3,259 percent, in January 2013, August 2014, May 2015, and September 2015,
respectively. Following dramatic price hikes between 2013 and 2015, the costs of several medications remained inflated through 2024, with some continuing to increase. Denavir (penciclovir) maintained its elevated price, with a 5g tube
retailing around $876 by 2024. Nilandron (nilutamide), used in prostate cancer treatment, reached about $3,319 for a 30-tablet supply, fluctuating between $3,000 and $5,500 in recent years. Dutoprol, a beta blocker, saw its price
soar more than 900% by 2015 and has since remained high, while Miacalcin (calcitonin) rose from $67 to $2,286 per vial in 2015 and continued to retail for around $246 per dose in 2024. Despite public scrutiny and policy discussions,
these medications have yet to return to pre-inflation price levels, underscoring ongoing concerns around drug affordability and pricing transparency in the U.S. pharmaceutical market.
- In the U.S. there are one device and 16 FDA approved drugs to treat brain tumors:
- Before 2010, the U.S. Food and Drug Administration (FDA) had approved six medications for the prevention of breast cancer,
primarily centered on the selective estrogen receptor modulators tamoxifen and raloxifene—marketed under names such as
Evista (Raloxifene Hydrochloride),
Keoxifene (Raloxifene Hydrochloride),
Nolvadex (Tamoxifen Citrate),
Raloxifene Hydrochloride, and
Tamoxifen Citrate.
These agents remain the cornerstone of preventive therapy, especially for women at high risk. Since then, no new drugs have been approved specifically for breast cancer prevention. However, the landscape of breast cancer treatment
has evolved dramatically since 2010, with the emergence of numerous targeted therapies. Among them are CDK4/6 inhibitors—palbociclib, ribociclib, and abemaciclib—for hormone receptor-positive, HER2-negative cases; PARP inhibitors
like olaparib and talazoparib for BRCA-mutated cancers; and advanced HER2-directed treatments such as ado-trastuzumab emtansine, trastuzumab deruxtecan, neratinib, and tucatinib. Additionally, immunotherapies such as atezolizumab and
pembrolizumab have been introduced for certain cases of triple-negative breast cancer, and PI3K inhibitor alpelisib offers a precision-medicine approach for patients with PIK3CA mutations. Together, these innovations signify
a major shift toward personalized, molecularly targeted treatment strategies across the breast cancer spectrum.
- Prescription sleeping pills such as Lunesta (eszopiclone), Ambien (zolpidem),
Restoril (temazepam), and Sonata (zaleplon) have been linked to a significantly
higher risk of early death, with studies suggesting that individuals who use these medications are up to four times more likely to die prematurely compared to nonusers. Even infrequent use has been associated with increased
mortality, with causes ranging from cancer and heart disease to respiratory problems and accidental injuries like falls or car crashes. Large-scale studies, including research from Scripps Clinic and Taiwan, support
these findings and suggest that sleeping pills may contribute to increased risks through mechanisms like respiratory suppression, cognitive impairment, depression, and immune system weakening. While these are observational
data and do not prove causation, they have prompted experts to urge caution with long-term use and recommend safer alternatives such as cognitive behavioral therapy for insomnia (CBT-I), lifestyle changes, and non-sedating treatments.
- A groundbreaking study led by researchers at Harvard Medical School found that daily doses of a Parkinson's drug—specifically
amantadine—significantly improved function in patients with severe brain injuries
who were previously considered beyond the reach of treatment. The trial provided the first rigorous evidence that pharmacological intervention could meaningfully aid recovery in patients in a minimally conscious state,
enhancing their ability to follow commands, communicate, and regain awareness. These findings challenged long-held assumptions about the limits of recovery after traumatic brain injury and opened new avenues for therapeutic
strategies targeting neural plasticity and arousal pathways.
- Cholesterol-reducing statin drugs, such as
Lipitor (atorvastatin),
Crestor (rosuvastatin),
Vytorin (simvastatin/ezetimibe), and
Zocor (simvastatin)
increased risks of Type 2 diabetes and memory loss for patients who take the medications.
However, in addition to lower cholesterol levels, statins may reduce the risk of death for
patients who have been hospitalized for influenza.
- Since 2023, the leading cause of overdose deaths in the U.S. has shifted away from prescription painkillers toward synthetic opioids like fentanyl, which were involved in over 72,000 deaths in 2023 alone. In contrast,
about 13,000 overdose deaths were linked to prescription opioids, while heroin accounted for roughly 4,000 and cocaine nearly 29,500. Even when combined, deaths from heroin and cocaine surpassed those from prescription opioids.
However, many overdoses involve multiple substances, blurring clear distinctions. Despite the continued risk posed by prescription painkillers, it's now illicit fentanyl and polysubstance use that dominate the overdose crisis.
- As of 2022, approximately 4% of adolescents aged 12 to 17 reported misusing prescription drugs, often obtaining them not from dealers, but from familiar sources—such as friends, family members, or unsecured medicine cabinets
at home. This easy access to leftover medications remains a major contributor to teen drug misuse, underscoring the importance of safely storing prescriptions, disposing of unused pills properly, and fostering open, honest
conversations about the dangers of misuse.
- According to the 2023 Monitoring the Future survey, after marijuana, prescription and over-the-counter (OTC) medications—such as Adderall, opioids, tranquilizers,
and cough medicines containing dextromethorphan (DXM)—rank among the most commonly misused substances by 12th graders. These drugs are often perceived as safer because they’re legal and widely available, but misuse can lead to
serious health risks, including addiction and overdose. Alcohol and nicotine vaping also remain prevalent, but when it comes to drug categories beyond marijuana, prescription and OTC medications are a major concern among teens.
- In 2024, drug-related emergency department visits reached approximately 1.6 million, highlighting the escalating toll of substance misuse on the healthcare system. Pharmaceuticals—especially opioids, benzodiazepines,
and antidepressants—were frequently involved, either on their own or in combination with other substances. The misuse of prescription drugs remains a key contributor to these emergencies, with the risks compounded when mixed with
alcohol or illicit drugs.
- In 2013, the U.S. spent $271.1 billion on prescription drugs—nearly one-tenth of the nation's total healthcare spending. A decade later, that figure soared to $449.7 billion in 2023, an 11.4% jump from the previous year.
By 2024, spending surged even further to an estimated $805.9 billion, driven largely by rising demand for costly medications like GLP-1 receptor agonists used for diabetes and weight loss. Despite this dramatic rise in dollar terms,
prescription drugs still accounted for about 9.2% of total national health expenditures in 2023—roughly the same proportion as in 2013, but nearly triple the cost.
- Approximately 52 million Americans—about 18.4% of those aged 12 and older—have misused prescription drugs at least once in their lifetime, placing them among the most widely abused substances. While earlier data ranked
prescription drugs third behind alcohol and marijuana, recent statistics indicate they now rank fifth, following alcohol, tobacco, marijuana, and cocaine. Despite this shift in position, prescription medications such as opioids,
sedatives, and stimulants continue to pose a major public health concern due to their high misuse potential, widespread availability, and risk of addiction or overdose.
- Roughly 16.3 million Americans misuse prescription medications each year, with rates highest among teens and young adults in their 20s, particularly for opioids, stimulants, and sedatives. While earlier surveys once estimated
that 20% of high school students had taken a prescription drug without a doctor's approval, more recent data suggests the actual figure is closer to 5% among 12th graders. Still, misuse remains a serious concern—and it's rising
among adults in their 50s and older, especially within the baby boomer generation, due to increased access to medications for chronic health conditions and a lower perceived risk of harm.
- In 2023, the FDA approved 55 novel drugs—one of the highest annual totals in recent decades—targeting conditions ranging from cancer and Alzheimer’s to rare genetic diseases, with over half of these treatments developed for
rare disorders and many fast-tracked through expedited pathways like priority review. In 2024, approvals remained robust with 50 novel drugs cleared, including a growing number of biologics and gene therapies addressing neurological,
infectious, and endocrine conditions. Compared to the 35 approvals in 2011, both years reflect a significant acceleration in drug development and regulatory responsiveness.
- After marijuana and alcohol, prescription medications—including opioids, stimulants, and cough syrups—rank among the most commonly misused substances by teens. Recent data indicates that approximately 2.5% of adolescents
aged 12 to 17 report misusing pain relievers each year, while about 5% of 12th graders admit to having misused any prescription drug. A major driver of this trend is the easy access teens have to these medications—often from friends,
relatives, or unsecured supplies at home—underscoring the urgent need for stronger prevention strategies, secure storage, responsible disposal, and open communication about the risks of misuse.
- Between 2022 and 2024, the U.S. saw a steady stream of new drug approvals, indicating a healthy and expanding pharmaceutical pipeline. The FDA approved 37 novel drugs in 2022, a slight decrease from previous years but
still significantly higher than the totals seen in 2008–2010. In 2023, approvals surged to 55—one of the highest counts in decades—followed by 50 more novel drug approvals in 2024. This upward trend reflects advances in
biotechnology and growing momentum in treatments for cancer, rare diseases, neurological disorders, and gene therapies, reinforcing the nation’s continued investment in innovative drug development.
- In 2008, the top 5 generic drugs sold in the US are
Hydrocodone/APAP ($1.78B),
Simvastatin ($1.45B),
Azithromycin ($1.3B),
Omeprazole ($1.15B), and
Metoprolol Succinate ($1.12B).
The rest....
By 2024, while precise sales rankings for individual generic drugs aren't as publicly detailed as they were in 2008, the generic drug market in the U.S. remains strong, with over 950 approvals in 2023 alone.
The landscape has shifted significantly: pain medications like Hydrocodone/APAP have declined in use due to opioid-related regulations; cardiovascular drugs such as Atorvastatin, Lisinopril, and Metoprolol remain widely prescribed;
and common medications like Omeprazole have shifted to over-the-counter status, affecting prescription-based sales. Antibiotic use, including Azithromycin, remains common but fluctuates with public health trends. Meanwhile,
biosimilars and complex generics are gaining prominence, and the industry continues to adapt to pricing pressures, supply chain challenges, and evolving treatment demands.
- Drug patent expirations (2008 & 2009) included some popular medications, such as
Acular (used for treat Eye pain),
Arimidex (Breast cancer),
Avandia (Diabetes),
Avelox (Antibiotic),
Cellcept (Organ rejection),
Flomax (BPH),
Glyset (Diabetes),
Imitrex (Migraine),
Keppra (Epilepsy),
Prevacid (Heartburn),
Valtrex (Herpes),
Xenical (Obesity),
Advair (Asthma),
Camptosar (Colon and rectum cancers),
Casodex (Prostate cancer),
Depakote (Epilepsy),
Effexor XR (Depression),
Fosamax (Osteoporosis),
Lamictal (Epilepsy),
Prograf (Organ rejection),
Risperdal (Schizophrenia),
Serevent (Asthma),
Sonata (Insomnia),
Topamax (Migraine),
Trusopt (Glaucoma), and
Zerit (HIV). Between 2010 and 2025, the U.S. experienced a substantial wave of drug patent expirations—often referred to as the "patent cliff"—which allowed
generic versions of many top-selling brand-name drugs to enter the market and significantly reshape the pharmaceutical industry. Hundreds of medications across key areas such as cardiovascular health, mental health, cancer,
and infectious diseases lost their exclusivity, including blockbusters like Lipitor, Plavix, Singulair, Cymbalta, and Abilify. From 2021 to 2024, dozens more patents expired, especially in oncology and immunology, and by 2025,
at least 65 additional drugs are expected to go off-patent. This 15-year stretch has played a major role in expanding access to treatment while driving down costs and encouraging a shift toward more complex generics and biosimilars.
- In 2007, the top 5 generic drugs used in hospitals in the US are
Lovenox ($1.44B),
Aranesp ($1.2B),
Procrit ($1.2B),
Revlimid ($1.15B), and
Neulasta ($978M).
The rest... In 2008, the top 5 branded drugs sold in the US are
Lipitor ($5.88B),
Nexium ($4.80B),
Plavix ($3.80B),
Advair Diskus ($3.57B), and
Prevacid ($3.3B).
The rest... In 2023 and 2024, the U.S. pharmaceutical market experienced a major shift
toward specialty and chronic disease treatments, with top-selling branded drugs reflecting the rising dominance of cancer therapies, metabolic treatments, and advanced biologics. In 2023, the five leading drugs by U.S. sales
were Keytruda ($25.0B, Merck), Humira ($14.4B, AbbVie), Ozempic ($14.0B, Novo Nordisk), Eliquis ($12.9B, BMS/Pfizer), and Biktarvy ($11.8B, Gilead Sciences). By 2024, Keytruda remained at the top with $29.5B in sales,
followed by Eliquis ($20.7B), Ozempic ($17.5B), Dupixent ($14.1B, Sanofi/Regeneron), and Biktarvy ($13.4B). These rankings highlight a growing demand for immunotherapies, GLP-1 receptor agonists for diabetes and weight loss,
and treatments for chronic and viral conditions, while older blockbusters like Humira lost ground due to biosimilar competition.
- There were a number of drug companies that paid billions of dollars
to the U.S. government to settle their bad practices on drugs, such as providing wrong advertisements, illegally encouraging doctors to prescribe unapproved drugs to patients, and manipulating prices to overcharge state and federal programs. Between 2006 and 2011, over 130 settlements were made, in which the most well-known ones were
Glaxo-SmithKline paid $3 billion in 2011, and
Pfizer and
Eli Lilly paid $2.3 billion and $1.4 billion, respectively, in 2009. Between 2006 and 2011, more than 130 settlements were reached between
pharmaceutical companies and the U.S. government over unethical practices such as misleading advertising, promoting unapproved drug uses, offering kickbacks to physicians, and overcharging public healthcare programs.
Notable cases include GlaxoSmithKline's $3 billion settlement in 2012—the largest healthcare fraud settlement at the time—alongside Pfizer's $2.3 billion and Eli Lilly's $1.4 billion payouts in 2009. Since then, even larger
agreements have been made, such as Johnson & Johnson and three major distributors paying $26 billion in 2021 for their role in the opioid crisis, and Purdue Pharma with the Sackler family agreeing to a $7.4 billion
opioid-related settlement in 2024. These cases underscore the ongoing scrutiny of pharmaceutical industry practices and the high financial stakes tied to corporate accountability in public health.
|
| |